Experimental vaccine plus immunotherapy shows promise against aggressive head and neck cancer

NCT ID NCT07572864

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen May 09, 2026 · Last updated May 24, 2026 · Updated 4 times

Summary

This study tests a new treatment for a type of head and neck cancer that is hard to cure. It combines an experimental vaccine that targets a protein called IMP3 with an immunotherapy drug. The goal is to shrink tumors before surgery and prevent them from coming back after. The trial is for 9 adults whose cancer is IMP3-positive and can be removed with surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

West China Hospital, Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, 610041, China
West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA